Advertisement

Ekso Bionics Holdings, Inc. EKSO

Set alert

Price alert · EKSO

All alert types
15.90 USD 0.00 0.00%

As of Jul 2, 3:24 PM ET

Bid
11.42 × 2
Ask
11.65 × 2
15.75 Day range 18.12
0.50 52-week range 3.13
YTD
+84.03%
1 year
+165.00%
Open
17.85
Prev close
15.90
Mkt cap
13.31M
Vol
133.57K
Avg vol
95.96K
EPS
-0.64
P/E
0.00
Div yield
0.00%
More statistics
Low
15.75
High
18.12
Forward P/E
-3.18
Beta
1.48
Short ratio
1.03
Inst. own
25.25%
Dividend
0.00
Ex-div date
50-d avg
0.81116
200-d avg
1.10
1y target
5.50

3M chart

Chart tools
Interval

Signals (16)
NameDateAgo
SMA: BullishApr 17, 20266 months ago
SMA: BullishApr 17, 20266 months ago
MACD: Buy SignalApr 16, 20266 months ago
SMA: BearishApr 2, 20267 months ago
SMA: BullishMar 31, 20267 months ago
SMA: BearishMar 30, 20267 months ago
SMA: BearishMar 26, 20267 months ago
SMA: BullishMar 25, 20267 months ago
SMA: BearishMar 18, 20267 months ago
MACD: Sell SignalMar 16, 20267 months ago
MACD: Buy SignalMar 9, 20267 months ago
MACD: Sell SignalFeb 24, 20268 months ago
RSI: OverboughtFeb 18, 20268 months ago
MACD: Buy SignalFeb 17, 20268 months ago
MACD: Sell SignalFeb 12, 20268 months ago
MACD: Buy SignalFeb 5, 20268 months ago

Key statistics

Market cap
13.31M
Enterprise value
10.82M
Trailing P/E
0.00
Forward P/E
-3.18
PEG ratio
0.00
Price / sales
0.75
Price / book
0.89
EPS (TTM)
-0.64
Beta
1.48
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-62.95%
Revenue (TTM)
17.68M
Revenue growth
-10.40%
Free cash flow
-4.85M
Total cash
8.29M
Total debt
6.35M
Return on equity
-73.89%
Shares outstanding
22.00M
Short % of float
0.57%
50-day average
0.81116
200-day average
1.10

Analyst view

Consensus: none

Price target (mean) 5.50 -65.4% downside
Target (low)
2.00
Target (mean)
5.50
Target (high)
9.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
  • Strong buy1
  • Buy1
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
EKSO Revenue — quarterly 2.14M
2022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 2026
EKSO Net income — quarterly -6.88M
2022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 2026
EKSO EPS — quarterly -2.04
2022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 2026

Earnings

EKSO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Oct 28, 2024Sep 1, 2024-0.08-0.10-0.02-25.00%
Jul 29, 2024Jun 1, 2024-0.11-0.13-0.02-18.18%
Apr 29, 2024Mar 1, 2024-0.16-0.20-0.04-25.00%
Mar 4, 2024Dec 1, 2023-0.11-0.22-0.11-100.00%
Oct 26, 2023Sep 1, 2023-0.31-0.24+0.07+22.58%
Jul 27, 2023Jun 1, 2023-0.28-0.31-0.03-10.71%

Upgrades / downgrades

EKSO analyst upgrades and downgrades
DateFirmActionFromTo
Oct 29, 2024Lake StreetmainBuyBuy
Oct 29, 2024HC Wainwright & Co.mainBuyBuy
Jul 30, 2024HC Wainwright & Co.reitBuyBuy
Jun 24, 2024Lake Streetinit—Buy
Apr 30, 2024HC Wainwright & Co.mainBuyBuy
Mar 5, 2024HC Wainwright & Co.mainBuyBuy

About Ekso Bionics Holdings, Inc.

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States

News

Your note

Sign in to keep a note on EKSO — it syncs with the Stock Master app.

Insider holders

EKSO insider holders
InsiderRelationLatest transactionDateShares held
CLOYD MARY ANNDirectorStock Award(Grant)Jun 5, 2024220,505
DAVIS SCOTT GERALDPresidentSaleAug 16, 2023331,372
JONES JASON CChief Operating OfficerStock Award(Grant)Mar 21, 20240
LATHAN CORINNADirectorStock Award(Grant)Jun 5, 2024226,207
LI KECHENGDirectorStock Award(Grant)Jun 5, 2024224,738
SCHER DEBORAH LAFERDirectorStock Award(Grant)Jun 5, 202478,217

Institution ownership

EKSO institution ownership
Holder% heldSharesValueReported
Armistice Capital, LLC9.85%2,167,0001.31MSep 29, 2024
Kent Lake PR LLC7.59%1,669,7001.01MSep 29, 2024
Vanguard Group Inc2.70%594,427359.63KSep 29, 2024
Cresset Asset Management, LLC2.34%515,615311.95KSep 29, 2024
Geode Capital Management, LLC0.76%167,308101.22KSep 29, 2024
Renaissance Technologies, LLC0.34%74,61645.14KSep 29, 2024

Fund ownership

EKSO fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.82%400,887242.54KSep 29, 2024
Vanguard Extended Market Index Fund0.82%179,455108.57KSep 29, 2024
Fidelity Extended Market Index Fund0.48%105,16363.62KOct 30, 2024
Fidelity Series Total Market Index Fund0.11%24,85415.04KOct 30, 2024
Fidelity Total Market Index Fund0.07%14,8388.98KOct 30, 2024
Vanguard Institutional Index-Inst Total Stock Market Ind0.06%14,0858.52KSep 29, 2024
Advertisement